Effect of a Structured Pharmaceutical Care Intervention Versus Usual Care on Cardiovascular Risk in HIV Patients on Antiretroviral Therapy: INFAMERICA Study.
Ramón Morillo-VerdugoMaría de Las Aguas Robustillo-CortésMaría Teresa Martín-CondeGador Callejón-CallejónPurificación Cid-SilvaCarmen Moriel-SánchezBegoña Tortajada-GoitiaCarmen Victoria Almeida-GonzálezPublished in: The Annals of pharmacotherapy (2018)
A total of 53 patients were included. As regards the main variable, 20.7% of patients reduced their Framingham-score from high/very high to moderate/low cardiovascular risk versus 12.5% in the control group ( P=0.016). In the intervention group, the number of patients with controlled blood pressure increased by 32.1% ( P=0.012); 37.9% of patients overall stopped smoking ( P=0.001), and concomitant medication adherence increased by 39.4% at the 48-week follow-up ( P=0.002). Conclusion and Relevance: Tailored pharmaceutical care based on risk stratification, motivational interviewing, and new technologies might lead to improved health outcomes in HIV+ patients at greater cardiovascular risk.
Keyphrases
- end stage renal disease
- antiretroviral therapy
- newly diagnosed
- ejection fraction
- blood pressure
- chronic kidney disease
- healthcare
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- human immunodeficiency virus
- clinical trial
- hepatitis c virus
- type diabetes
- hiv positive
- quality improvement
- patient reported outcomes
- smoking cessation
- insulin resistance
- study protocol
- hypertensive patients